The company reports on its financial performance on a quarterly basis starting its financial year on January 01.
Results published on July 25, 2024.
The company reports on its financial performance on a quarterly basis starting its financial year on January 01.
Arno Groenewoud (July 2024)
Chief Financial Officer
For 2024 – excluding unforeseen events – the company expects QUVIVIQ net sales of around CHF 55 million; SG&A expenses of around CHF 300 million; R&D expense of around CHF 145 million for Idorsia-led pipeline assets; non-GAAP operating expenses of up to CHF 455 million. This performance would result in a non-GAAP operating loss of around CHF 400 million (excluding contract revenues and the one-off benefit from the Viatris deal).
The company expects US GAAP operating loss for 2024 to reach CHF 320 million which includes a one-off benefit of CHF 125 million from the Viatris deal.
First Half |
||
in CHF millions, except EPS (CHF) and number of shares (millions) |
2024 |
2023 |
Net revenues |
26 |
51 |
Operating expenses |
(94) |
(426) |
Operating income (loss) |
(64) |
(375) |
Net income (loss) |
(79) |
(405) |
Basic EPS |
(0.44) |
(2.28) |
Basic weighted average number of shares |
179.5 |
178.1 |
Diluted EPS |
(0.44) |
(2.28) |
Diluted weighted average number of shares |
179.5 |
178.1 |
Net revenue of CHF 26 million in the first half of 2024 is the result of QUVIVIQ product sales and contract revenue recognized in connection with Owkin (CHF 3 million). This compares to CHF 51 million in the first half of 2023, which included CHF 32 million sales of PIVLAZ in Japan (assigned in the meantime to Nxera Pharma as part of a transaction, more details can be found in the dedicated press release) and CHF 2 million revenue share from Johnson & Johnson related to ponesimod sales (revenue-sharing agreement now eliminated as part of the reacquisition of aprocitentan, more details can be found in the dedicated press release).
US GAAP operating expenses in the first half of 2024 benefited from extraordinary income of CHF 125 million from the Viatris deal resulting in an expense of CHF 94 million (CHF 426 million in the first half of 2023), of which CHF 4 million related to cost of sales (CHF 5 million in the first half of 2023), CHF 71 million to R&D expenses (CHF 172 million in the first half of 2023), and CHF 142 million to SG&A expenses (CHF 249 million in the first half of 2023).
US GAAP net loss in the first half of 2024 amounted to CHF 79 million (CHF 405 million net loss in the first half of 2023). The decrease of the net loss is mainly attributable to the one-off income related to the Viatris deal but was also driven by lower operating expenses throughout all functions.
The US GAAP net income resulted in a basic net loss per share of CHF 0.44 (basic and diluted) in the first half of 2024, compared to a net loss per share of CHF 2.28 (basic and diluted) in the first half of 2023.
First Half |
||
in CHF millions, except EPS (CHF) and number of shares (millions) |
2024 |
2023 |
Net revenues |
26 |
51 |
Operating expenses |
(200) |
(393) |
Operating income (loss) |
(170) |
(342) |
Net income (loss) |
(183) |
(369) |
Basic EPS |
(1.02) |
(2.07) |
Basic weighted average number of shares |
179.5 |
178.1 |
Diluted EPS |
(1.02) |
(2.07) |
Diluted weighted average number of shares |
179.5 |
178.1 |
Non-GAAP net loss in the first half of 2024 amounted to CHF 183 million: the CHF 104 million difference versus US GAAP net income was mainly due to the one-off effect of the Viatris deal (CHF 125 million income), depreciation and amortization (CHF 8 million), and share-based compensation (CHF 10 million).
The non-GAAP net loss resulted in a net loss per share of CHF 1.02 (basic and diluted) in the first half of 2024, compared to a net loss per share of CHF 2.07 (basic and diluted) in the first half of 2023.
At the end of the first half of 2024, Idorsia’s liquidity amounted to CHF 237 million.
Type of debt | Jun 30, 2024 |
March 31, 2024 |
Dec 31, 2023 |
Convertible loan |
CHF 335 million | CHF 335 million | CHF 335 million |
Convertible bond |
CHF 797 million | CHF 797 million | CHF 796 million |
Other financial debt |
CHF 162 million | CHF 162 million | CHF 162 million |
Total indebtedness | CHF 1,294 million |
CHF 1,293 million |
CHF 1,293 million |
* rounding difference may occur
Here we provide a 5-year archive of our financial reports and related reporting documentation.
Results published on July 25, 2024.
Results published on May 21, 2024:
Results published on May 21, 2024:
Results published on October 24, 2023:
Results published on July 25, 2023:
Results published on April 25, 2023:
Results published on February 7, 2023:
Results published on October 25, 2022:
Results published on July 26, 2022:
Results published on April 26, 2022:
Results published on February 8, 2022:
Results published on October 26, 2021:
Results published on July 27, 2021:
Results published on April 22, 2021:
Results published on February 4, 2021:
Results published on October 27, 2020:
Results published on July 23, 2020:
Results published on April 23, 2020:
Results published on February 6, 2020:
Results published on October 22, 2019:
Results published on July 23, 2019:
Results published on April 18, 2019: